Advertisement

Topics

Survival Success Prompts Early Halt to Opdivo-Yervoy Study

06:05 EDT 8 Sep 2017 | PharmPro

CheckMate -214 study evaluating Opdivo in combination with Yervoy stopped early for demonstrating overall survival benefit in patients with previously untreated advanced or metastatic renal cell carcinoma.
Contributed Author: 

Original Article: Survival Success Prompts Early Halt to Opdivo-Yervoy Study

NEXT ARTICLE

More From BioPortfolio on "Survival Success Prompts Early Halt to Opdivo-Yervoy Study"

Quick Search
Advertisement
 

Relevant Topics

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...